May 17 2016
Sep 18 2015
Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study of Growth-Hormone-XTEN (VRS-317, Somavaratan) in Children (Amunix out-licensed VRS-317, a fusion protein consisting of rhGH and XTEN, to Versartis in 2008).
Read about it here: Versartis Study Announcement
Launch of our new website!
We want to hear from you. How can we improve our website? Your suggestions, ideas, complaints will greatly help us. Please send us your comments or suggestions via our contact form (Website Feedback) tab.